T2 Biosystems, Inc.
TTOO · OTC
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $1,985 | $1,952 | $2,061 | $1,679 |
| % Growth | 1.7% | -5.3% | 22.8% | – |
| Cost of Goods Sold | $4,101 | $2,693 | $4,202 | $2,648 |
| Gross Profit | -$2,116 | -$741 | -$2,141 | -$969 |
| % Margin | -106.6% | -38% | -103.9% | -57.7% |
| R&D Expenses | $2,667 | $3,361 | $3,721 | $3,095 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $5,378 | $5,473 | $6,738 | $5,255 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $8,045 | $8,834 | $10,459 | $8,350 |
| Operating Income | -$10,161 | -$9,575 | -$12,600 | -$9,319 |
| % Margin | -511.9% | -490.5% | -611.4% | -555% |
| Other Income/Exp. Net | $44 | $612 | -$934 | -$1,021 |
| Pre-Tax Income | -$10,117 | -$8,963 | -$13,534 | -$10,340 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$10,117 | -$8,963 | -$13,534 | -$10,340 |
| % Margin | -509.7% | -459.2% | -656.7% | -615.8% |
| EPS | -0.57 | -0.64 | -2.66 | -2.08 |
| % Growth | 10.9% | 75.9% | -27.9% | – |
| EPS Diluted | -0.57 | -0.64 | -2.66 | -2.08 |
| Weighted Avg Shares Out | 17,893 | 14,095 | 5,088 | 4,969 |
| Weighted Avg Shares Out Dil | 17,893 | 14,095 | 5,095 | 4,969 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $370 | $478 | $1,179 | $1,161 |
| Depreciation & Amortization | $59 | $62 | $64 | $74 |
| EBITDA | -$9,688 | -$8,423 | -$12,291 | -$9,105 |
| % Margin | -488.1% | -431.5% | -596.4% | -542.3% |